WAICF
4.4.2022 16:05:06 CEST | Business Wire | Press release
The World AI Cannes Festival (WAICF) is the first global event dedicated exclusively to AI, to tech leaders who innovate in the field and to the economic, human and societal issues which will impact our lives in the very near future. While the first two days will be dedicated to professionals, on the last day of the event, the Palais des Festivals et des Congrès in Cannes will open its doors to the public.
A discovery day for the general public
On Saturday, April 16, WAICF will become a hub of discovery, learning and reflection on AI. This day will give visitors a chance to discover five thematic zones
.
Each zone will feature a special area for demonstrations and immersive experiences.
WAICF presents AI in the sectors of well-being, beauty, health and luxury. Visit the stands of tomorrow’s key players and enjoy unique experiences in the demonstration areas and Take advantage of the relaxation area to unwind and enjoy the innovative new experiences on offer in this sector.
An exhilarating experience awaits in 140m² of space dedicated to demonstrating AI advances in the field of sport. Test out different sports putting Artificial Intelligence to use, meet industry players and discover AI solutions on offer.
For the first edition of WAICF, the entire first floor of the Palais des Festivals is transformed into an exhibition space focusing on the intersection of Artificial Intelligence and Art. Independent contemporary art curator, Marnie Benney, brings together artists in an inspiring program that includes.
Farming, agriculture, energy, mobility, meet the AI experts working for the good of the environment and discover their innovative solutions.
Experts, speakers and recruiters will be present to welcome the general public in a 135m² space dedicated to Human Resources and present the latest innovations of Artificial Intelligence in this field.
Discover all the experiences on the WAICF website .
Accreditation
I n order to request for your accreditation for the WAICF, from 14 to 16 April at Cannes, please write an email to : waicf@agence-profile.com
About the WAICF
The World AI Cannes Festival was born out of the desire to bring together businesses and individuals in Artificial Intelligence. Through a rich and diverse line up, attendees are invited to discover and understand the many ways in which artificial intelligence impacts our daily lives. The World AI Cannes Festival also presents a unique opportunity for businesses to be exposed to innovative ideas, novel information, and new findings. Businesses will be called to showcase their knowledge and experiences as well as to network with leading industry players and decision makers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005559/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 13:00:00 CEST | Press release
Global brands including Bosch, Castrol, Coca-Cola Al Ahlia Beverages, and Moët Hennessy take the stage in Barcelona as Kinaxis sets the direction for the next era of supply chain Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 13:00:00 CEST | Press release
The Danish medtech company's ear-EEG platform can now be placed on the European market, enabling clinicians to record multi-day and multi-night EEG in the patient's home for epilepsy, sleep and other neurophysiological research and care. Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom